Literature DB >> 19022361

The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.

Marcel Ferrer-Alcón1, David Arteta, M José Guerrero, Dietmar Fernandez-Orth, Laureano Simón, Antonio Martinez.   

Abstract

The advent of functional genomics has been greatly broadening our view and accelerating our way in numerous medical research fields. The complete genomic data acquired from the human genome project and the desperate clinical need of comprehensive analytical tools to study complex diseases, has allowed rapid evolution of genomic and proteomic technologies, speeding the rate and number of discoveries in new biomarkers. By jointly using genomics, proteomics and bioinformatics there is a great potential to make considerable contribution to biomarker identification and to revolutionize both the development of new therapies and drug development process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022361     DOI: 10.1016/j.toxlet.2008.10.014

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  3 in total

1.  Monitoring molecular-specific pharmacodynamics of rapamycin in vivo with inducible Gal4->Fluc transgenic reporter mice.

Authors:  Mei-Hsiu Pan; Jeffrey Lin; Julie L Prior; David Piwnica-Worms
Journal:  Mol Cancer Ther       Date:  2010-09-21       Impact factor: 6.261

2.  Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.

Authors:  Lawson Eng; Irada Ibrahim-zada; Hamdi Jarjanazi; Sevtap Savas; Mehran Meschian; Kathleen I Pritchard; Hilmi Ozcelik
Journal:  BMC Med Genomics       Date:  2011-02-11       Impact factor: 3.063

Review 3.  Development of proteomics-based fungicides: new strategies for environmentally friendly control of fungal plant diseases.

Authors:  Francisco Javier Fernández Acero; María Carbú; Mohamed Rabie El-Akhal; Carlos Garrido; Victoria E González-Rodríguez; Jesús M Cantoral
Journal:  Int J Mol Sci       Date:  2011-01-21       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.